1. Oily core/amphiphilic polymer shell nanocapsules change the intracellular fate of doxorubicin in breast cancer cells.
- Author
-
Coelho JM, Camargo NS, Ganassin R, Rocha MCO, Merker C, Böttner J, Estrela-Lopis I, Py-Daniel KR, Jardim KV, Sousa MH, Ombredane AS, Joanitti GA, Silva RC, Azevedo RB, Longo JPF, and Muehlmann LA
- Subjects
- Animals, Breast Neoplasms pathology, Castor Oil, Cell Line, Cell Line, Tumor, Cell Nucleus, Cytoplasm, Doxorubicin toxicity, Drug Carriers standards, Humans, MCF-7 Cells, Mice, NIH 3T3 Cells, Breast Neoplasms drug therapy, Doxorubicin metabolism, Drug Carriers chemistry, Nanocapsules chemistry
- Abstract
The aim of this work was to develop and test the in vitro biological activity of nanocapsules loaded with a doxorubicin (DOX) free base dissolved in a core of castor oil shelled by poly(methyl vinyl ether-co-maleic anhydride) conjugated to n-octadecylamine residues. This system was stable and monodisperse, with a hydrodynamic diameter of about 300 nm. These nanocapsules changed the intracellular distribution of DOX, from the nuclei to the cytoplasm, and exhibited higher toxicity towards cancer cells - 4T1 and MCF-7 - and significantly lower toxicity towards normal cells - NIH-3T3 and MCF-10A - in vitro. In conclusion, these nanocapsules are suitable DOX carriers, which remain to be studied in in vivo tumor models.
- Published
- 2019
- Full Text
- View/download PDF